[HTML][HTML] Inhibition of the anti-apoptotic protein MCL-1 severely suppresses human hematopoiesis
S Bohler, S Afreen, J Fernandez-Orth… - …, 2021 - ncbi.nlm.nih.gov
S Bohler, S Afreen, J Fernandez-Orth, EM Demmerath, C Molnar, Y Wu, JM Weiss…
Haematologica, 2021•ncbi.nlm.nih.govBH3-mimetics inhibiting anti-apoptotic BCL-2 proteins represent a novel and promising
class of antitumor drugs. While the BCL-2 inhibitor venetoclax is already approved by the
Food and Drug Administration, BCL-XL and MCL-1 inhibitors are currently in early clinical
trials. To predict side effects of therapeutic MCL-1 inhibition on the human hematopoietic
system, we used RNA interference and the small molecule inhibitor
class of antitumor drugs. While the BCL-2 inhibitor venetoclax is already approved by the
Food and Drug Administration, BCL-XL and MCL-1 inhibitors are currently in early clinical
trials. To predict side effects of therapeutic MCL-1 inhibition on the human hematopoietic
system, we used RNA interference and the small molecule inhibitor
Abstract
BH3-mimetics inhibiting anti-apoptotic BCL-2 proteins represent a novel and promising class of antitumor drugs. While the BCL-2 inhibitor venetoclax is already approved by the Food and Drug Administration, BCL-XL and MCL-1 inhibitors are currently in early clinical trials. To predict side effects of therapeutic MCL-1 inhibition on the human hematopoietic system, we used RNA interference and the small molecule inhibitor
ncbi.nlm.nih.gov
